Inhalable insulin

History

Insulin was discovered by Sir Frederick G Banting, Charles H Best, and JJR Macleod from the University of Toronto in 1921 as an injectable agent. German researchers first introduced the idea of inhalable insulin in 1924. Years of failure followed until scientists realized they might be able to use new technologies to turn insulin into a concentrated powder with particles sized for inhalation.

In the 1980s Nektar Therapeutics, based on work by A. Carl Leopold on vitrifying proteins, developed technology to make insulin into small particles, technology then licensed to Pfizer. Alkermes developed a delivery device that they licensed to Eli Lilly and Company.

Once concrete methods were developed, human tests began in the late 1990s. In January 2006, the U.S. Food and Drug Administration (FDA) approved the use of Exubera, a form of inhalable insulin developed by Pfizer. It was approved in the UK in August 2006 but reimbursed by the National Health Service only for people who had problems with needles. It was not reimbursed by any US insurer. A 2007 systematic review concluded that the inhaled hexameric insulin (Exubera) "appears to be as effective, but no better than injected short-acting insulin. The additional cost is so much more that it is unlikely to be cost-effective." In 2007, Pfizer announced that it would no longer manufacture or market Exubera. According to Chairman and CEO Jeffrey Kindler this was because Exubera "failed to gain acceptance among patients and physicians".

At the time of Exubera's discontinuation, several other companies were pursuing inhaled insulin including Alkermes working with Eli Lilly and Company, MannKind Corporation, and Aradigm working with Novo Nordisk. By March 2008, except for MannKind's Afrezza product, all of these products had been discontinued because investors all decided to withdraw funding.

On March 16, 2009 MannKind submitted a new drug application for their inhalable insulin. In 2011 the FDA denied approval of Afrezza; because the design of the delivery device had changed, it requested additional clinical trials to ensure that people would use it the same way as the earlier versions. After conducting further studies, Mannkind submitted a new application, and in June, 2014, the FDA approved Afrezza for both Type I and Type II adult diabetics, with a label restriction for patients having asthma, active lung cancer or COPD. In 2014 Mannkind and Sanofi agreed that Sanofi would take over manufacturing and marketing of Afrezza, but Sanofi said it was dropping the effort in January 2016 due to poor sales of $7.5 million in 2015; the companies formally terminated the agreement in November 2016. At the time that Sanofi announced it was dropping the product Mannkind said it would continue alone,

References

References

1. (June 2010). "Pharmacologist". Annals of Pharmacotherapy.
2. (August 2016). "Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need?". Advances in Therapy.
3. (June 27, 2014). "FDA approves Afrezza to treat diabetes". U.S. Food and Drug Administration.
4. "100 Years of Insulin".
5. (August 4, 2006). "Inhaled insulin given UK launch". BBC News.
6. (August 2016). "Commentary: Why Was Inhaled Insulin a Failure in the Market?". Diabetes Spectrum.
7. (January 19, 2011). "MannKind Corporation Receives Complete Response Letter from the FDA for AFREZZA(R)". MannKind Corporation.
8. (May 2015). "US Afrezza label". FDA.
9. (August 11, 2014). "Sanofi fills some big shoes in $925M Afrezza pact with MannKind". FierceBiotech.
10. (February 10, 2016). "Sanofi tried and failed with Afrezza. Why does MannKind still think it can win?". FiercePharma.
11. (November 10, 2016). "Sanofi forgives MannKind's boatload of debt over failed Afrezza deal". FiercePharma.
12. (2018-07-01). "Improved Time-in-Range (TIR) on Continuous Glucose Monitor (CGM) with Technosphere Inhaled Insulin (TI) Compared with Insulin Aspart in T1D Patients—STAT Study". Diabetes.
13. Gillis, Justin. (January 28, 2006). "Inhaled Form of Insulin Is Approved". The Washington Post.
14. (September 2007). "The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation". Health Technology Assessment.
15. Simons, John. (19 October 2007). "How the Exubera debacle hurts Pfizer". CNNMoney.
16. (January 1, 2007). "Alkermes Inc. AIR Inhaled Insulin System Human insulin inhalation powder Began Phase III trial to evaluate effectiveness in improving glucose control vs. injected premeal insulin in 400 patients 4/06 Type II diabetes". Bioworld Today.
17. (2007). "Technosphere Insulin - How it works". MannKind Corp.
18. Pollack, Andrew. (November 16, 2007). "Betting an Estate on Inhaled Insulin". The New York Times.
19. Lilly/Alkermes—RIP, AIR Insulin, Close Concerns, Inc. Company Watch, Diabetes Close Up #78, www.diabetescloseup.com.